MedTrace Logo

Safety Study of SGN-CD70A in Cancer Patients

NCT02216890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-04-19

No results posted yet for this study

Summary

This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.

Conditions

  • Renal Cell Carcinoma
  • Mantle-Cell Lymphoma
  • Diffuse, Large B-Cell, Lymphoma
  • Follicular Lymphoma, Grade 3

Interventions

DRUG

SGN-CD70A

Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)

Sponsors & Collaborators

  • Seagen Inc.

    lead INDUSTRY

Principal Investigators

  • Elaina Gartner, MD · Seagen Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-02-15
Completion
2017-02-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02216890 on ClinicalTrials.gov